Liver Failure  >>  emricasan (IDN 6556)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emricasan (IDN 6556) / Amerimmune
NCT01937130 / 2012-004245-33: Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Terminated
2
23
US, Europe
IDN-6556, emricasan, PF-03491390, Placebo
Conatus Pharmaceuticals Inc.
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
01/15
02/15

Download Options